Sector
PharmaceuticalsOpen
₹262.05Prev. Close
₹262.05Turnover(Lac.)
₹43.73Day's High
₹262.9Day's Low
₹252.1552 Week's High
₹44952 Week's Low
₹145Book Value
₹107.09Face Value
₹5Mkt Cap (₹ Cr.)
761.97P/E
24.84EPS
10.55Divi. Yield
0.47Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 14.16 | 14.14 | 14.13 | 14.42 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 299.79 | 321.63 | 381.55 | 356.02 |
Net Worth | 313.95 | 335.77 | 395.68 | 370.44 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Revenue | 387.96 | 372.82 | 299.26 | 19.35 |
yoy growth (%) | 4.06 | 24.57 | 1,446.28 | 54.73 |
Raw materials | -144.19 | -123.64 | -82.67 | 0 |
As % of sales | 37.16 | 33.16 | 27.62 | 0 |
Employee costs | -59.36 | -57.49 | -50.03 | -5.67 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Profit before tax | 42.56 | 63.22 | 47.54 | -25.64 |
Depreciation | -23.67 | -19.03 | -14.93 | -3.78 |
Tax paid | -12.32 | -11.26 | 16.12 | 22.97 |
Working capital | 15.97 | 18.66 | 5.68 | 214.15 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 4.06 | 24.57 | 1,446.28 | 54.73 |
Op profit growth | -18.97 | 34.86 | -1,216.24 | -33.65 |
EBIT growth | -26.46 | 21.59 | -790.19 | -24.49 |
Net profit growth | -41.81 | -18.37 | -2,484.03 | -88.94 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 335.66 | 349.94 | 398.52 | 377.29 | 292.95 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 335.66 | 349.94 | 398.52 | 377.29 | 292.95 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 11.81 | 8.6 | 8.14 | 8.25 | 12.32 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.85 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,001.1 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,478.5 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,137.55 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,413.35 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Director
Satish Varma
Company Sec. & Compli. Officer
Srikant N Sharma
Executive Vice Chairman & WTD
Krishna Datla
Non Executive Director
Rajeshwari Datla
Executive Director
ANUPAMA DATLA DESAI
Independent Director
Rajashri Santosh Kumar Ojha
Managing Director
Prashant Nagre
Independent Director
Pramod Kasat
Chairman & Independent Directo
Pradeep Manjunath Chandan
Independent Director
Ramanand Mundkur
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Fermenta Biotech Ltd
Summary
Fermenta Biotech Limited was formerly incorporated as Duphar-Interfran Limited in May, 1951. The Company name was changed to DIL Limited in September, 2003 and later on, the name was further changed to Fermenta Biotech Limited on October 17, 2019.The Company is engaged in the business of manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations and environmental solution products and renting and selling of properties. The Company has strategic investments in subsidiaries primarily dealing in manufacturing and marketing bulk drugs.In the initial years, the company manufactured and sold toothpaste, anti-septic lotion and pharmaceutical specialities on a loan-licence basis. It entered into collaborations with Philips-Duphar, Amsterdam (Solvay Duphar), and the Crookes Laboratories, London. These collaborators participated in the equity capital of the company to the extent of 25% each.In 1964, Company entered into a collaboration with Solvay Duphar to manufacture vitamin D3. In 1976, it entered into another collaboration with Solvay Duphar to manufacture isoxypurine hydrochloride -- a vasodilator. In 1976, in compliance with the FERA, the foreign collaborators reduced thier stake to 38.86%.Company came out with a rights issue in May 95 to augment long-term resources and working capital requirements. The company also sold its popular analgesic brand Crocin to Smithkline Beecham Pharmaceuticals. It also sold another OTC brand, Lacto-Calamine lotion t
Read More
The Fermenta Biotech Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹258.9 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Fermenta Biotech Ltd is ₹761.97 Cr. as of 09 May ‘25
The PE and PB ratios of Fermenta Biotech Ltd is 24.84 and 2.45 as of 09 May ‘25
The 52-week high/low is the highest and lowest price at which a Fermenta Biotech Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Fermenta Biotech Ltd is ₹145 and ₹449 as of 09 May ‘25
Fermenta Biotech Ltd's CAGR for 5 Years at 1.82%, 3 Years at 7.61%, 1 Year at 58.72%, 6 Month at -22.03%, 3 Month at -37.14% and 1 Month at -3.32%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.